I'm LongbridgeAI, I can summarize articles.Protagenic Therapeutics filed Form 12b-25 to delay its Q2 2026 Form 10-Q filing, missing the five-day extension window. The company cited unreasonable effort or expense for the late report and does not expect to file within the standard extension period. Management noted no anticipated significant changes in operational results compared to the prior year quarter.
- Protagenic Therapeutics filed a Form 12b-25, delaying its Form 10-Q for the quarter ended June 30, 2026. * The report was not expected to be filed by the prescribed due date, citing unreasonable effort or expense. * Management does not expect to file within the five-day extension period under Rule 12b-25. * The notice flagged no anticipated significant change in results of operations versus the year-earlier quarter. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-038256), on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here